Solution Development: A Model For Structuring Biotechs And Developing Better Drugs
Executive Summary
The biopharma industry must think differently about funding high-risk/reward development of drug candidates against novel targets. Multiplexing Phase II proof-of-concept trials can light a path toward lower-risk pivotal studies and provide a model for building biotechs to deliver what patients, providers, payors, and investors all want: solutions.